30 Day Trial

OrthoGrid Gains FDA Clearance for PhantomMSK Platform


OrthoGrid Systems received FDA 510(k) clearance to market the PhantomMSK™ intraoperative surgical imaging platform.


PhantomMSK provides correction for fluoroscopic distortion in multiple procedures, including direct anterior approach total hip arthroplasty, where it is designed to help restore native hip biomechanics with alignment considerations for leg length, femoral offset, cup inclination, femoral abduction, pelvic tilt, and pelvic obliquity.

OrthoGrid Systems will introduce PhantomMSK next month at AAOS.

Sources: OrthoGrid Systems, Inc.; ORTHOWORLD Inc.